Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.
In an interview with HCPLive®, Philip J. Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, discussed the complex relationship IBD has with some rheumatology disease and how some of the medications available could be effective against both families of disorders.
For example, tofacitinib is currently being used or tested for patients with inflammatory bowel disease, as well as rheumatoid arthritis and psoriatic arthritis.
The oral Janus kinase inhibitor was the subject to several abstracts presented virtually during the European Congress of Rheumatology (EULAR) 2020 meeting.
Mease presented a number of new studies, including the SELECT-PsA-2 trial highlighting upadacitinib as a treatment for psoriatic arthritis.
Upadacitinib, an oral, reversible, JAK inhibitor currently approved for treatment of moderate to severe rheumatoid arthritis, has the potential to be a frontline treatment for patients with psoriatic arthritis.
The rheumatologist explained how the effectiveness of treatments tend to wane overtime for this patient population, highlighting the importance of developing new medications.
Mease also explained some of the ongoing trials testing rheumatology treatments for effectiveness against the coronavirus disease 2019 (COVID-19), including JAK inhibitors.